Publications

Gurley, K.E. and Kemp, C.J. p53 induction, cell cycle arrest, and apoptosis in DNAPK-deficient scid mice. Carcinogenesis 17:2537-2542, 1996.

Gersten, K.M. and Kemp, C.J. Normal meiotic recombination in p53-deficient mice. Nature Genet. 17:378-379, 1997. Gurley, K.E., Vo, K. and Kemp, C.J. DNA double-strand breaks, p53, and apoptosis during lymphomagenesis in scid/scid mice. Cancer Res. 58:3111-3115, 1998.

Fero, M.L., Randel, E., Gurley, K.E., Roberts, J. and Kemp, C.J. The murine gene p27/Kip1 is haploinsufficient for tumour suppression. Nature 396:177-180, 1998.

Philipp, J., Vo, K., Gurley, K.E., Seidel, K. and Kemp, C.J. Tumor suppression by p27/Kip1 and p21/Cip1 during chemically induced skin carcinogenesis. Oncogene 18:4689-4698, 1999.

Kemp, C.J., Vo, K., and Gurley, K.E. Resistance to skin tumorigenesis in DNAPK-deficient SCID mice is not due to immunodeficiency but results from hypersensitivity to TPA-induced apoptosis. Carcinogenesis 20:2051-2056, 1999.

Kemp, C.J., Kim, K-H. and Philipp, J. The murine gene Cdkn1b (p27Kip1) maps to distal Chromosome 6 and is excluded as Pas1. Mammalian Genome 11:402-404, 2000.

Kemp, C.J., Sun, S. and Gurley, K.E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor type dependent. Cancer Res. 61:327-332, 2001.

Philipp-Staheli,J., Payne, S.R. and Kemp, C.J. p27Kip1: Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264:148-168, 2001.

Gurley, K.E., and Kemp, C.J. Synthetic lethality between mutations in Atm and DNAPK during murine embryogenesis. Current Biology 11:191-194, 2001.

Philipp-Staheli, J., Kim, K.-H., Payne, S.R., Gurley, K.E., Liggitt, D., Longton, G. and Kemp, C.J. Pathway specific tumor suppression: Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice but not Smad 3 mutant mice. Cancer Cell 1:355-368, 2002.

Payne, S.E. and Kemp, C.J. p27Kip1 (Cdkn1b) deficient mice are susceptible to chemical carcinogenesis and may be a useful model for carcinogen screening. Toxicologic Pathology, 31:335-363, 2003.

Philipp-Staheli, J. Kim, K.-H., Liggitt, D., Gurley, K.E., Longton, G., and Kemp, C.J. Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development. Oncogene, 23:905-913, 2004.

Kelly-Spratt, K.S. Gurley, K.E., Yasui,Y., and Kemp,C.J. p19Arf suppresses growth, malignant conversion, and metastasis of Hras-driven squamous cell carcinomas through p53 dependent and independent pathways. PLoS Biology, 2:1138-1149, 2004.

King, T.J., Gurley, K.E., Prunty, J.A., Shin, J.L., Kemp, C.J. and Lampe, P.D., Deficiency in the gap junction protein Connexin32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner. Oncogene, 24:1718-1726, 2005.

Zhang, H., Yi, E.C., Li, X.J., Mallick, P., Kelly-Spratt, K.S., Masselon, C.D., Camp, D.G., Smith, R.D., Kemp, C.J., Aebersold, R. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol. Cell Proteomics. 4:144-155, 2005.

Li, X.J.., Yi, E.C., Zhang, H., Kemp, C.J., Aebersold, R.. A Software Suite for the Generation and Comparison of Peptide Arrays from Sets of Data Collected by Liquid Chromatography-Mass Spectrometry. Mol. Cell Proteomics. 4:1328-1340, 2005. Kemp, C.J. Multistep skin cancer in mice as a model to study the evolvability of cancer cells. Semin. Cancer Biol., 15:460-473, 2005.

Payne, S.E. and Kemp, C.J. Tumor suppressor genetics. Carcinogenesis, 26:2031-2045, 2005.

Besson, A., Gurian-West, M., Chen, X., Kelly-Spratt, K., Kemp, C.J., Roberts, J.M. A pathway in quiescent cells that controls p27/Kip1 stability, subcellular localization, and tumor suppression. Genes and Devel., 20:47-64, 2006.